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OBJECTIVE—Digenic causes of human disease are rarely re-
ported. Insulin via its receptor, which is encoded by INSR, plays
a key role in both metabolic and growth signaling pathways.
Heterozygous INSR mutations are the most common cause of
monogenic insulin resistance. However, growth retardation is
only reported with homozygous or compound heterozygous
mutations. We describe a novel translocation [t(7,19)(p15.2;
p13.2)] cosegregating with insulin resistance and pre- and post-
natal growth deﬁciency. Chromosome translocations present a
unique opportunity to identify modifying loci; therefore, our
objective was to determine the mutational mechanism resulting
in this complex phenotype.
RESEARCH DESIGN AND METHODS—Breakpoint mapping
was performed by ﬂuorescence in situ hybridization (FISH) on
patient chromosomes. Sequencing and gene expression studies
of disrupted and adjacent genes were performed on patient-
derived tissues.
RESULTS—Affected individuals had increased insulin, C-pep-
tide, insulin–to–C-peptide ratio, and adiponectin levels consis-
tent with an insulin receptoropathy. FISH mapping established
that the translocation breakpoints disrupt INSR on chromosome
19p15.2 and CHN2 on chromosome 7p13.2. Sequencing demon-
strated INSR haploinsufﬁciency accounting for elevated insulin
levels and dysglycemia. CHN2 encoding -2 chimerin was shown
to be expressed in insulin-sensitive tissues, and its disruption
was shown to result in decreased gene expression in patient-
derived adipose tissue.
CONCLUSIONS—We present a likely digenic cause of insulin
resistance and growth deﬁciency resulting from the combined
heterozygous disruption of INSR and CHN2, implicating CHN2
for the ﬁrst time as a key element of proximal insulin signaling in
vivo. Diabetes 58:2954–2961, 2009
T
he genetic susceptibility to insulin resistance can
involve the disruption of a single gene (e.g.,
INSR) or may involve the interplay of many
genetic loci (including PPARG, FTO, HNF1B,
etc.). However, there is currently only one known digenic
disorder of insulin resistance resulting from mutations
in peroxisome proliferator–activated receptor gamma
(PPARG) and protein phosphatase 1 regulatory subunit 3
(PPPTR3A) (1). Compound heterozygous mutations in
these genes, which are primarily involved in carbohydrate
or lipid metabolism, respectively, can combine to produce
a phenotype of extreme insulin resistance and lipodystro-
phy (1). Interestingly, individuals who possess only one
mutation have normal insulin levels demonstrating that
disruption of both genes and therefore pathways is neces-
sary to result in disease (1).
INSR encodes the insulin receptor with a key role in
both major arms of the insulin signaling pathways, specif-
ically the metabolic pathway mainly via IRS-1/Akt2/AS160
signaling and the growth pathway mainly via IRS-2/extra-
cellular signal–related kinase (ERK) signaling (2). INSR
mutations are the most common cause of monogenic insulin
resistance and cause a clinical spectrum of disease ranging
from type A insulin resistance to the most severe form of
insulin receptoropathy, leprechaunism (also known as Dono-
hue’s syndrome) (3–6).
Growth is a complex biological process with multiple
interacting pathways. The key pathways involved in
growth include the insulin signaling pathway and the
growth hormone/insulin-like growth factor pathway (7–9).
Intrauterine growth is also regulated by multiple fetal and
maternal factors including genetic and epigenetic factors
and various environmental factors (10).
We describe a family with a reciprocal translocation
[t(7,19)(p15.2;p13.2)] cosegregating with insulin resistance
and pre- and postnatal growth deﬁciency. We demonstrate
that the breakpoint on chromosome 19 disrupts INSR,
causing monoallelic expression. Haploinsufﬁcent INSR
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severe growth deﬁciency (5). Given the short stature and
intrauterine growth retardation also seen in this family, we
hypothesized this could be due to either complete loss of
the functional INSR protein (due to the second INSR allele
harboring a mutation or due to a dominant negative effect
of a mutant INSR protein) or a digenic syndrome due to
disruption of a second gene involved in growth by the
chromosome 7 breakpoint. The ﬁrst two hypotheses were
excluded by the demonstration of a normal INSR DNA
sequence and monoallelic INSR expression, while further
cytogenetic analysis established that the second break-
point on chromosome 7p15.2 disrupted CHN2 encoding
-2 chimerin. The demonstration that disruption of CHN2
affects both pre- and postnatal growth suggests that chi-
merins may play an important role in early growth and
development.
RESEARCH DESIGN AND METHODS
We report a family with pre- and postnatal growth deﬁciency, insulin
resistance, and early-onset diabetes (Table 1). The female proband was born
at term weighing 1.85 kg (5th centile), and all other intrauterine growth
parameters were 5th centile (Table 1). Her growth was maintained below
the 5th centile. She was hypoglycemic at birth and treated with intravenous
10% glucose infusion for 36 h. She has mild dysmorphic features with a
triangular face, irregular teeth, hypertrichosis, a masculine appearance, and
no history of miscarriage. The proband was diagnosed with diabetes requiring
insulin treatment at age 15 years and since then has been on insulin therapy
with variable dosage, notably requiring less insulin throughout pregnancy and
dietary treatment alone for 2 months postnatally. She is currently managed
with gradually increasing insulin doses (see supplementary methods Table 1,
available in an online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-0787/DC1). Her fasting insulin and C-peptide levels are
greatly elevated (Table 1). Karyotype analysis identiﬁed the following karyo-
type: [46, XX, t(7,19)(p15.2;p13.2)].
The proband’s son was the ﬁrst-born child of a nonconsanguineous
marriage delivered by caesarean section at 35 weeks’ gestation. Aminocente-
sis at 16 weeks’ gestation identiﬁed the following karyotype [46, XY,
t(7,19)(p15.2;p13.2)]. The son weighed 1.9 kg (10th centile), and his length
was 5th centile (Table 1). He has no dysmorphic features. He had recurrent
neonatal hypoglycemia and was noted to have preprandial hypoglycemia and
postprandial hyperglycemia at age 3 months. His fasting insulin and C-peptide
levels were greatly elevated (Table 1). He is currently age 22 months and
continues on dietary management; his growth trajectory remains below the
3rd centile.
The proband’s parents are nonconsanguineous and have no evidence of
diabetes, growth retardation, or dysmorphic features. The height of the
proband’s mother, father, and older sister is 162, 174, and 173 cm, respectively.
Chromosomal analysis in both parents revealed a normal karyotype.
Biochemical analysis. Insulin and C-peptide levels were assayed using a
radioimmunoassay (Immunotech, Prague, Czech Republic). Adiponectin was
also assayed using a radioimmunoassay (Linc, Millipore, U.K.), and normative
data were acquired from 27 healthy control subjects.
Bioinformatic tools. The University of California Santa Cruz Web site
(http://genome.ucsc.edu/), Online Mendelian Inheritance in Man (OMIM)
(www.ncbi.nlm.nih.gov), and GeneSniffer (www.genesniffer.org) were used to
identify and prioritize biological candidate genes within the region of both
breakpoints.
Chromosome preparation, DNA isolation, and establishment of patient
cell lines. Peripheral blood samples were obtained from the proband and her
son, and conventional methods were used to prepare metaphase spreads for
FISH analysis, extract genomic DNA, and establish an Epstein-Barr virus
(EBV)-transformed lymphoblastoid cell line.
Fluorescence in situ hybridization analysis. Fluorescence in situ hybrid-
ization (FISH) analysis was performed using standard techniques (see online
supplementary methods).
Gene dosage investigations. Multiplex ligation-dependent probe ampliﬁca-
tion (MLPA) and SYBR green analysis were used to quantify gene dosage of
INSR and CHN2, respectively (see online supplementary methods).
TABLE 1
Clinical and biochemical characteristics of patients with the novel translocation
Proband Son (10th centile)
Current age (years) 24 2
Gestational age (weeks) 40 35
Birth weight (kg) (5th–95th centile) 1.85 (2.69–4.03) 1.9 (1.84–3.2)
Length at birth (cm) (5th–95th centile) 43 (43.47–52.69) 39 (44.08–49.7)
Head circumference at birth (cm) 33 (10th centile) 32
Current weight (kg) 38 10.3 (3rd centile)
Current height (cm) (mid-parental height) 145 (161) 80 ( 3rd centile)
Current BMI (kg/m
2) (normal range) 18 (19–25) 16 (15–18)
Acanthosis nigricans No No
Hypertrichosis (facial, limbs, and trunk) Yes (aged 11 years) No
Menarche (years) 11 —
Age at diagnosis of hyperglycemia (years) 15.9 (symptoms from age 10 years) 0.25
Current treatment Insulin Diet
Glucose in the neonatal period (mmol/l)
(normal 2.6 mmol/l) 3.2 1.4
Fasting glucose at diagnosis (mmol/l) (normal
7 mmol/l) 11.2 2.3–8 (preprandially)
Ketonuria Trace Negative
Autoantibodies (GAD, IA2A) Negative Negative
Insulin (pmol/l) (5th–95th centile) 3,724 (15.2–159) 6,025 (18–46.8)
C-peptide (pmol/l) (normal 160–1,100 pmol/l) 2,931 8,081
Insulin–to–C-peptide ratio (normal 0.1) 1.27 0.74
Adiponectin (ng/ml)* 22.3 26.1
Triglycerides (mmol/l) 0.62 (0.55–1.9) 1.0
Cholesterol (mmol/l) 3.9 (3.5–5.5) 4.3 (3.8–4.5)
HDL (mmol/l) 1.62 (0.8–1.8) 1.61 (0.82–0.94)
LDL (mmol/l) 1.68 (0.8–2.2) 2.05
IGF-1 (normal range for age) 873 ng/ml (90–500) 203.7 ng/ml (70–380)
Proteinuria (normal range) (mg/24 h) 353.4 (30) (pre-pregnancy) NA
Data are control means (95% CI) unless otherwise indicated. *Range for adults (9.8 / 1.26 ng/ml). NA, not available.
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and sequenced on an ABI 3700 genetic analyzer (Applied Biosystems, War-
rington, U.K.). Sequences were compared with the published sequence
(NM_000208) using Mutation Surveyor version 3.4 (Softgenetics, Cambridge,
U.K.). The entire cDNA sequence of INSR was ampliﬁed in nine overlapping
fragments and sequenced as above. Coding sequences with known single
nucleotide polymorphisms (SNPs) of CHN2 and adjacent biologically plausi-
ble genes (GHRHR, JAZF1, GRB10) were ampliﬁed and sequenced in patient
genomic DNA. All primer sequences are available in the online supplementary
methods.
RNA extraction, retrotranscription, and gene expression studies. RNA
was extracted and retrotranscribed from patient EBV–transformed lympho-
blastoid cell lines, and the proband’s subcutaneous adipose tissue was
obtained by needle biopsy using standard methods (see online supplementary
methods). A commercially available RNA library from a standard panel of
tissues (Human Total RNA Master Panel II) was purchased from Clontech
(Saint-Germain-en-Laye, France). Gene expression analysis was performed by
quantitative real-time PCR (qRT-PCR) on an ABI 7900HT analyzer using
inventoried and designed assays (Applied Biosystems). Data were normalized
to the mean of three housekeeping genes (11). Details of assays and
housekeeping genes are provided in the online supplementary methods.
RESULTS
Karyotype analysis revealed an apparently balanced trans-
location [t(7,19)(p15.2;p13.2)] in both the proband and her
affected son. The proband’s unaffected parents had normal
karyotypes, suggesting the translocation arose de novo in
the proband. We hypothesized that the breakpoint of this
translocation disrupted one or more genes involved in the
etiology of the insulin resistance and growth deﬁciency in
both subjects. Bioinformatics identiﬁed a total of 67 genes
within the breakpoint regions on chromosomes 19p13.2
and 7p15.2. The most plausible biological candidate was
INSR on chromosome 19. Biochemical analysis showed
raised insulin, C-peptide, insulin–to–C-peptide ratio, and
adiponectin levels in both individuals, suggesting disrup-
tion of INSR (Table 1).
FISH analysis of proband chromosomes using bacterial
artiﬁcial chromosomes (BACs) and fosmids narrowed
down the region of the breakpoint on chromosome 19 to
an 10-Kb region entirely within the genomic sequence of
INSR (Figs. 1A and 2A), predicted to be between exons 13
and 15. To investigate possible cryptic microdeletions
within the INSR sequence, MLPA analysis was performed
in both patients. Taking into account the resolution limits
of FISH, we decided to perform MLPA analysis on a
broader DNA region spanning exons 11–17. A microdele-
tion between 2.4–6.6 Kb in size including exons 15 and 16
was detected (Fig. 2C). Direct sequencing of the entire
coding region of INSR in patient genomic DNA excluded
an INSR mutation. An informative heterozygous SNP
(c.1650GA;p.A550A) identiﬁed in patient genomic DNA
was shown to be monoallelic in patient RNA, establishing
INSR haploinsufﬁciency and excluding a potential domi-
nant negative mutational mechanism (Fig. 2D). Reduced
INSR expression in both patient-derived EBV cell line and
adipose tissue cDNA was also demonstrated (Fig. 2E
and F).
To explain the clinical phenotype observed in this family
and determine the mutational mechanism for the growth
deﬁciency, we also mapped the translocation breakpoint
on chromosome 7. A number of strong biological candi-
date genes for growth mapped to the region including
JAZF1 (12–14) and GHRHR (15). Disruption of both genes
was excluded by FISH analysis (data not shown), while
gene expression studies on patient EBV–transformed lym-
phocyte cell line derived–cDNA, compared with healthy
control subjects, demonstrated that JAZF1 expression
was not altered (see online supplementary results Fig. 1).
GHRHR is only expressed in the pituitary so it was not
possible to investigate patient gene expression levels. To
exclude a growth hormone–releasing hormone (GHRH)
receptor defect, the proband underwent a GHRH-arginine
stimulation test that illustrated a normal response (see
online supplementary results Table 1).
Further mapping on chromosome 7 restricted the break-
point to 25.3 Kb entirely within the genomic sequence of
CHN2 (Figs. 1B and 2B). Gene dosage studies established
that there was no loss of the coding region of CHN2 (data
not shown). Monoallelic CHN2 expression could not be
demonstrated as no informative coding SNPs were identi-
ﬁed in patient genomic DNA. Gene expression studies
established that CHN2 is expressed in human brain and
insulin-sensitive tissues including liver, adipose tissue
(subcutaneous and omental), and muscle (Fig. 3A). Ex-
pression analysis in patient adipose tissue–derived cDNA
compared with healthy control subjects demonstrated
reduced CHN2 expression (Fig. 3B).
Given the proximity of the translocation breakpoint to
an imprinted region on the chromosome implicated in
Silver-Russell syndrome (SRS) and the possibility of a
positional effect of the translocation on gene expression,
we excluded involvement of GRB10—the SRS candidate
gene in this region—by establishing that GRB10 gene
expression levels were normal in patient adipose tissue
(see online supplementary results Fig. 2) (16). Monoallelic
GRB10 expression could not be conﬁrmed due to a lack of
informative coding SNPs in the GRB10 coding sequence.
DISCUSSION
Digenic causes of human disease are rare in the literature
but present an opportunity to model possible gene-gene
interactions, which may provide insights into common
metabolic disorders including type 2 diabetes. We report a
family with a novel reciprocal translocation [t(7,19)(p15.2;
p13.2)] resulting in the ﬁrst reported case of severe insulin
resistance, diabetes, and growth deﬁciency resulting from
the synergistic disruption of INSR and CHN2.
It is well established that INSR mutations are the most
common cause of monogenic insulin resistance. Most
mutations are missense mutations in the  subunit that
have dominant negative activity. However, truncating mu-
tations have a similar effect. Biochemical features support-
ing the diagnosis of an INSR defect in the family described
include markedly elevated insulin and C-peptide levels as
a response to severe insulin resistance and due to reduced
insulin clearance (17), a raised insulin–to–C-peptide ratio
(17), and raised adiponectin levels relative to the degree of
insulin resistance in these subjects (18). This is conﬁrmed
by our genetic investigations, which demonstrated disrup-
tion of INSR by a reciprocal translocation and monoallelic
INSR expression. However, our genetic studies at the
INSR locus do not explain the severe pre- and postnatal
growth deﬁciency observed in both subjects. Variable
penetrance of INSR haploinsufﬁciency may result in phe-
notypic heterogeneity. Published evidence from the par-
ents of children with Donohue’s syndrome shows that
haploinsufﬁcient parents have a mildly deranged or normal
metabolic phenotype, although some may have marked
insulin resistance. However, this is usually in the presence
of obesity or other risk factors (5,19).
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more severe autosomal recessive insulin receptoropathies
(Donohue’s syndrome and Rabson-Mendenhall syn-
drome). Both affected individuals have an intermediate
phenotype with neonatal hypoglycemia, severe insulin
resistance, hyperglycemia in childhood, and intrauterine
and postnatal growth deﬁciency; however, they have no
evidence of premature mortality. The proband also has
mild dysmorphic features with minimal subcutaneous fat,
overdeveloped musculature (masculinization), and abnor-
mal dentition—all features seen in severe autosomal re-
cessive insulin receptoropathies.
The genotype-phenotype correlation in patients with
INSR mutations is likely to be affected by the mutation site
and possible modiﬁer loci (20). Moreover, evidence from
mice that are double heterozygous for null alleles in insr
and irs-1 (insr/irs-1/) genes display a synergistic
effect on insulin resistance with a 5- to 50-fold rise in
insulin levels despite the expected 50% reduction in the
protein levels of INSR and IRS-1 (21), suggesting that
A
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FIG. 1. A: Map of the INSR region on chromosome 19p13.2 illustrating the BACs and fosmids selected for FISH analysis. BACs (150–200 Kb in
size) and fosmids (40 Kb in size) overlapping over the entire genomic sequence of INSR were selected and obtained for FISH analysis. Also
shown are the results of FISH analysis, which demonstrated that the minimal breakpoint region is 10.8 Kb and all within the genomic sequence
of INSR. B: Map of the CHN2 region on chromosome 7p15.1 illustrating the BACs and fosmids selected for FISH analysis. BACs (150–200 Kb
in size) and fosmids (40 Kb in size) overlapping the entire genomic sequence of CHN2 were selected and obtained for FISH analysis. Also shown
are the results of FISH analysis, which demonstrated that the minimal breakpoint region is 25.3 Kb and all within the genomic sequence of CHN2.
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FIG. 2. A: FISH analysis showing disruption of the BAC CTD-2560C1 containing the genomic sequence of INSR. As shown, the digoxigenein-labeled
BAC CTD2560C1 (red) spans the breakpoint as there are three signals apparent where it hybridizes to chromosome 19, derivative chromosome 19,
and derivative chromosome 7. The two chromosome 7 homologs are identiﬁed by a ﬂuoroisothiocyanate (FITC)-labeled chromosome-speciﬁc paint
(green). Chromosomes are counterstained with DAPI (blue). B: FISH analysis showing disruption of the BAC RP11-980H8 containing the genomic
sequence of CHN2. As shown, the digoxigenein-labeled BAC RP11-980H8 (red) spans the breakpoint with three signals apparent where it hybridizes
to chromosome 7, derivative chromosome 7, and derivative chromosome 19. The two chromosome 7 homologs are identiﬁed by a FITC-labeled
chromosome-speciﬁc paint (green). Chromosomes are counterstained with DAPI (blue). C: Identiﬁcation of a cryptic microdeletion (exons 15–16)
within INSR using MLPA. Graph of normalized gene dosage of INSR exons 11–17 and control HNF1A and HNF4A exons run at the same time. Dosage
quotients were calculated from average crossing points of triplicate samples using the comparative Ct (Ct) method. A ratio of 1 implies normal gene
dosage, and a ratio below 0.75 suggests a deletion. Exons 15 and 16 of INSR are deleted with a ratio of less than 0.75. D: Demonstration of monoallelic
expression of INSR in a patient-derived lymphoblastoid cell line. The exon 8 silent variant, c.1650G>A, p.A550A, is heterozygous in genomic DNA, but
sequencing of patient cDNA reveals monoallelic expression due to the heterozygous SNP only showing one allele at c.1650G. E: INSR gene expression
studies in the proband’s subcutaneous adipose tissue–derived cDNA showed reduced expression compared with that from three BMI-matched samples.
F: INSR gene expression studies in patient EBV cell line–derived cDNA showed reduced expression in both the proband and her affected son compared
with a healthy control sample. (A high-quality color digital representation of this ﬁgure is available in the online issue.)
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insulin resistance. In this family, we have the rare oppor-
tunity to deﬁne a possible modiﬁer locus by mapping the
second breakpoint of the translocation. Mapping of the
breakpoint on chromosome 7 demonstrated disruption of
CHN2, which encodes -2 chimerin. Chimerins are ligand-
activated Rac-speciﬁc GTPase-activating proteins (22),
which are expressed in many human tissues, especially
brain, pancreas, and insulin-sensitive tissues. Chimerins
are downstream effectors of tyrosine kinase receptors and
S.G.I. SULIMAN AND ASSOCIATES
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manner via suppression of Rac and extracellular signal–
related kinase phosphorylation (23). Decreased expres-
sion of CHN2 is associated with high-grade malignant
gliomas, duodenal adenocarcinomas, and breast tumors
(23), suggesting that chimerins are tumor suppressors;
however, increased expression of CHN2 is reportedly
associated with lymphomas (24). We therefore propose
that reduced CHN2 expression, a gene with a known role
in growth pathways, contributes to a novel digenic syn-
drome of insulin resistance and dysglycemia due to dis-
ruption of INSR combined with marked pre- and postnatal
growth deﬁciency due to disruption of CHN2.
There is a possible role for phenotypic modiﬁcation
caused by disruption of regulation of other biologically
plausible genes close to the chromosome 7p breakpoint as
there are several strong biological contenders. Although
these genes are a long way from the breakpoint, disruption of
the spatial relationship between these genes and unknown
regulatory elements, as seen with other translocations, can-
not be excluded (25). GHRHR maps to chromosome 7p15.2,
and mutations in GHRHR are a known cause of dwarﬁsm of
Sindh (15). However, a GHRH test performed on the proband
conﬁrmed a normal response, thereby excluding a defect in
the GHRH receptor. JAZF1 on chromosome 7p15.1–15.2 is a
recently described type 2 diabetes susceptibility gene with a
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FIG. 3. A: Expression proﬁle of CHN2 in a panel of healthy human tissues to identify tissue distribution, shown is the expression in brain and
insulin-sensitive tissues. The ratio of CHN2 expression relative to the mean of three housekeeping genes (PPIA, GAPDH, and 18s) was analyzed
in a panel of human tissues. B: CHN2 expression is reduced in patient adipose tissue–derived cDNA compared with that of three matched healthy
control samples. Gene expression studies to identify the expression levels of CHN2 (relative to the mean of three housekeeping genes) were
performed using a combination of inventoried and designed assays to cover all known transcripts of CHN2. All transcripts of CHN2 were reduced
in patient subcutaneous (SC) adipose tissue (AT) compared with those of three healthy control subjects (mean control).
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sion levels are not altered in either the proband or her son.
SRS has also been linked to chromosome 7p, and the
minimal overlap region has been delineated to chromosome
7p11.2, 25 Mb away from the breakpoint (26). This region
contains multiple biological candidates with the strongest
evidence supporting GRB10 (16). GRB10 encodes growth
factor receptor binding protein 10, which is also known as
insulin receptor binding protein and is maternally imprinted
(16). Mice carrying maternally inherited targeted deletions of
grb10 display a growth phenotype that recapitulates the SRS
phenotype described in patients (16). However, our investi-
gations have shown that there are no differences in GRB10
gene expression levels in the proband and her son compared
with normal healthy control subjects.
In summary, we describe a novel cytogenetic defect
resulting in a syndrome of severe insulin resistance, dys-
glycemia, and pre- and postnatal growth deﬁciency. The
simultaneous heterozygous disruption of INSR and CHN2
without loss of other candidate growth-related genes in
the region suggests this represents a novel digenic disor-
der and implicates CHN2 for the ﬁrst time in insulin’s
metabolic and growth-promoting actions in vivo.
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